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OBJECTIVES:More than 7000 rare diseases have been identified, and mostly have a
genetic disorder. In 1983, the Orphan Drug Act was implemented in the United
States to encourage the development of drugs for rare diseases. Since then, many
orphan drugs have been developed but payers concern about their high prices due
to a limited health care budget. In this article we tried to find a solution against lack
of methodologies and evidences for pricing and reimbursement of orphan drugs
and represent the results graphically. METHODS: Cerezyme, Myozyme and Ela-
prase are reimbursed for rare diseases in Korea. We adopted 3 products to estimate
the affordable threshold in cost-effectiveness plane along two properties: 1) reflec-
tion of the cost increase in the health care budget, and 2) index of effectiveness
including the prevalence, severity and efficacy for each product. Then we modeled
a new product by changing its properties and showed results. RESULTS: We de-
fined and analyzed the function of affordable threshold based on cost and index of
effectiveness in two dimensions. The index of effectiveness was calculated from
0.60 to 0.85 and median cost was distributed between 1.8 and 3.0 hundred million
won per year approximately. The affordable threshold for new drug highly depends
on weights of prevalence, severity and efficacy. CONCLUSIONS: Evidences for rare
diseases are often generated from the surrogate outcome, small population and no
comparator. Therefore, it is difficult to assess cost-effectiveness of drugs for rare
diseases with current approach. We showed that the affordable threshold can be
calculated by the products’ properties and monitoring periodically. This method
needs the social agreement for weights and we discuss further limitations.
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OBJECTIVES: 1) Review all Medicare national coverage determinations (NCDs) from
2007 through 2011 to identify how CER was explicitly an impetus for or considered
in the decision, and 2) Make inferences on Medicare’s future use of CER from past
behavior and recent health reform developments. METHODS: We reviewed docu-
mentation to identify whether a comparative study or health technology assess-
ment (HTA) was cited in Medicare’s decision initiation rationale or referenced in
the decision. Specifically, we determined the: 1) Number of NCDs and degree to
which CER was used; 2) Types of products and services (e.g., device, procedure); 3)
Therapeutic areas; 4) Organizations producing technical CER materials; 5) Inclusion
of cost effectiveness; and 6) Frequency and content of a coverage with evidence
development (CED) requirement. We characterized Medicare’s historical coverage
and payment behavior and prognosticated on how aspects of health reform may
affect future CER use. RESULTS: More than 55% or 36 NCDs considered CER, with
radiological procedures and diagnostic/screening tests comprising over half.
Sources for the CER technical work were 5 US and 5 international organizations.
Eleven of the decisions considered cost effectiveness; 4 reported a cost-effective-
ness ratio. While a minority, CED judgments increased over time. Medicare has
historically covered and set reimbursement levels that allow for the cost of care
plus some profit, only recently and selectively considering evidence of comparative
clinical or cost effectiveness. While provisions of the Affordable Care Act and reg-
ulatory changes promote the greater use of CER, there are official and practical
impediments that serve as a counterbalance. CONCLUSIONS: Medicare increas-
ingly will use CER in making NCDs but in ways less straightforward than predicted.
While many methods are available to Medicare, perhaps the most promising in the
current political environment are evidence threshold “creep”, CED, and several
novel applications of CER to coverage, coding, and pricing.
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OBJECTIVES: 1) Perform a comprehensive review of the US molecular testing envi-
ronment; 2) Infer from RESULTS:Diagnostic/treatment areas most likely to include
comparative effectiveness reviews (CER) involving molecular testing, how CER will
be shaped by molecular diagnostics, evidence used in coverage decisions; and 3)
Determine global generalizability of US trends. METHODS: We reviewed: 1) All
non-perinatal molecular tests with actual or potential for CER interface, all Medi-
care national (NCDs) and selected local coverage decisions (LCDs) involving molec-
ular tests and CER, and US government and related agency high priority disease
areas for CER, assessing actual or potential molecular testing inclusion, and 2) We
inferred: Clinical areas most likely involving molecular diagnostics and CER,iIm-
pact of molecular testing on CER, evidence required for Medicare/other payer cov-
erage, and universality of US findings. RESULTS: 1) Inventory indicates 442 molec-
ular tests/combinations of interest; 259 have potential degrees of CER interface; 2)
Medicare database yielded: 2 NCDs (Screening DNA Stool Test for Colorectal Can-
cer, Pharmacogenetic Testing for Warfarin Response), 9 LCDs and articles: many
denials of molecular test coverage, denials cite lack of evidence, including trials,
clinical utility, and few cite cost-effectiveness data; 3) Five governmental or health
technology assessment organizations point to 14 clinical areas as highest CER pri-
orities: six known to have associated molecular tests; 5 already involved CER ac-
tivity, and another 7 predicted to have future molecular testing and CER activity per
identified priority areas for research. CONCLUSIONS: Expect molecular testing: to
play an increasing future role in CER, particularly in 7 areas (cancer and hemato-
pathology most prominently, inclusion will necessitate more methodologically so-
phisticated CER, will make cost-effectiveness part of CER, will require strong clin-
ical utility evidence for payer coverage, and trends will be universal and more
pronounced ex-US.
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OBJECTIVES:Verification whether social implications were considered in HTA pro-
cess in Poland and the UK. METHODS: The comparative analysis included follow-
ing stages: 1) HTA recommendations issued in the period of January 2010 to May
2011 for AHTAPol and September 2010 to May 2011 for NICE; 2) HTA recommenda-
tions were labeled as positive, negative or other (when outcome was neither posi-
tive nor negative); 3) Check-list was composed on the basis of INAHTA definition of
social issues in HTA and also of a definition which additionally introduced changes
in equity and access as a social effect of implementation of a technology. Social
issues were grouped in 6 categories; and 4) The impact of consideration of social
implications in HTA recommendations was determined. RESULTS: Total of 132
AHTAPol Recommendations and 13 NICE Technology Appraisals issued in 2010
were reviewed (in 2 cases, because of the lack of evidence, NICE was unable to make
a recommendation). Social implications were found in respectively: 27% and 82% of
recommendations. The impact of social implications on HTA recommendations
was more common in the UK. In total 59 and 12 were reviewed for AHTAPoL and
NICE, social implications were found in respectively: 46% and 83% of recommen-
dations. The impact of social implications on HTA recommendations was more
common in the UK. Social implications, frequently raised by AHTAPol during the
analyzed period, were: changes in access to health care (48%), influence on pa-
tient’s functioning in society (15%), patient’s ability to work (14%) and others (21%
- mainly, avoidable hospitalization). NICE paid more attention to: changes in access
to health care (26%), influence on patient’s functioning in society (15%), influence
on subcultures (15%) and others (35% - mainly, discrimination). CONCLUSIONS:
During the analyzed period, NICE considered social implications more frequently
than AHTAPol. NICE and AHTAPol paid attention to different types of social impli-
cations.
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OBJECTIVES: In the UK, the National Institute for Health and Clinical Excellence
(NICE) assesses the cost-effectiveness of therapies in England and Wales. In Scot-
land, the Scottish Medicines Consortium (SMC) is responsible for such decisions.
There are recognised differences in how these agencies operate, with the SMC
adopting an early, rapid approach to health technology appraisal and NICE favour-
ing a more extensive, detailed review. Conflicting decisions between the two agen-
cies can lead to differential drug availability; however, it is generally believed that
the recommendations are broadly the same. The purpose of this review is to eval-
uate the level of agreement over the last year. METHODS: The NICE website was
searched for single technology appraisals (STAs) published between January and
December 2010. The appraisals for the same drugs were identified on the SMC
website and the recommendations of NICE and the SMC compared. RESULTS:
Nineteen STAs were performed by NICE in 2010. These included 11 drugs for cancer
indications and an assortment of 8 others. Of the 19 drugs evaluated, NICE recom-
mended 12 and rejected 7. For the same drugs, the SMC recommended 8 and
rejected 11. Decisions between the agencies were the same for 13 drugs, equating to
agreement in 68.4% of cases. Of the 6 cases where the recommendation differed, 5
were recommended by NICE. In all five cases the SMC found that the economic
cases presented by the manufacturers were not sufficiently robust: in one instance
weaknesses in the clinical data were also implicated. The one drug recommended
by the SMC in contradiction of NICE was also rejected based on cost-effectiveness.
CONCLUSIONS: In general, there is reasonable agreement between decisions made
by NICE and the SMC. Poor evidence regarding cost-effectiveness is the most com-
monly cited reason for one agency not recommending a drug.
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OBJECTIVES: Capacity constraints jeopardize health care systems’ sustainability
all over the world while the number of Health Technology Assessment (HTA) agen-
cies continues to increase. Explicit or implicit use of cost-effectiveness thresholds
based on HTA/economic evaluations should indicate whether a technology is
worth its costs. Personalized cancer medicine (PCM) promises to be different from
established technologies raising the question whether decision making also differs
for PCM. Our goal was to identify cost-effectiveness thresholds in general or spe-
cific to PCM to finally provide input for decision makers and expert panels.
METHODS: A conceptual evaluation framework was developed comprising eight
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